These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17179003)

  • 21. Adalimumab in juvenile rheumatoid arthritis.
    Sfriso P; Ravaioli F
    N Engl J Med; 2008 Dec; 359(23):2495; author reply 2496-7. PubMed ID: 19052133
    [No Abstract]   [Full Text] [Related]  

  • 22. [Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].
    Molina Molina MI; Pinochet Paiva CM; Quezada Morales JI
    Medwave; 2015 Dec; 15(11):e6350. PubMed ID: 26819061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 24. Adalimumab-induced asthma.
    Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
    [No Abstract]   [Full Text] [Related]  

  • 25. Adalimumab in juvenile rheumatoid arthritis.
    Taddio A; Marchetti F
    N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
    [No Abstract]   [Full Text] [Related]  

  • 26. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 28. Alopecia universalis during treatment with leflunomide and adalimumab - case report.
    Lazzarini R; Capareli GC; Buense R; Lellis RF
    An Bras Dermatol; 2014; 89(2):320-2. PubMed ID: 24770511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 30. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 31. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab-associated pulmonary fibrosis reply.
    Huggett MT; Armstrong R
    Rheumatology (Oxford); 2007 Aug; 46(8):1379-80; author reply 1379. PubMed ID: 17553912
    [No Abstract]   [Full Text] [Related]  

  • 33. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

  • 34. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
    Tomono K; Hashimoto S
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 36. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
    Brunasso AM; Scocco GL; Massone C
    J Rheumatol; 2010 Jul; 37(7):1549-50. PubMed ID: 20595297
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of adalimumab in treatment of autoimmune sensorineural hearing loss: a word of caution.
    Conway R; Khan S; Foley-Nolan D
    J Rheumatol; 2011 Jan; 38(1):176; author reply 176. PubMed ID: 21196585
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
    Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
    Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.